💰 Financial Performance

Revenue Growth by Segment

While absolute revenue figures are not disclosed, the Net Capital Turnover Ratio improved by 43.12% (from 5.96 to 8.53), indicating significantly higher revenue generation efficiency. The IT & Software Solutions segment is reported as seeing 'accelerated growth' compared to the 'foundational' Healthcare Services segment.

Geographic Revenue Split

Not disclosed in available documents, though the company mentions expansion into 'emerging markets' and 'underserved regions' for its healthcare screening services.

Profitability Margins

Net Profit Ratio improved from 0.08% to 0.11% YoY. While the margin remains thin, the Return on Equity (ROE) saw a substantial relative increase of 426%, rising from 0.19% to 1.00% for the financial year ended March 31, 2024.

EBITDA Margin

Core profitability as measured by Return on Capital Employed (ROCE) improved from 0.18% to 0.64%, representing a 255% YoY increase in capital efficiency.

Capital Expenditure

The company's paid-up capital increased by INR 12.44 Cr (from INR 7.10 Cr to INR 19.54 Cr) following the issuance of 1,24,38,296 equity shares for the amalgamation with Plus Care Internationals Private Limited.

Credit Rating & Borrowing

The Debt-wise Ratio (Debt-to-Equity) increased from 0.76 to 1.21, indicating a 59.2% increase in leverage to fund operations and the recent merger. Specific interest rates are not disclosed.

⚙️ Operational Drivers

Raw Materials

As a service-oriented firm, the primary 'raw materials' are Human Capital (Specialist Physicians and IT Engineers) and Diagnostic Consumables for laboratory services.

Capacity Expansion

The company expanded its operational footprint through the merger with Plus Care Internationals Private Limited, which added 10,348 shares of the transferor company's value into the consolidated entity.

Raw Material Costs

Not disclosed in available documents; however, the company highlights 'attraction and retention of human capital' as a major cost-related risk.

Manufacturing Efficiency

Not applicable as a service provider; however, the Net Capital Turnover Ratio of 8.53 indicates high asset-light efficiency.

📈 Strategic Growth

Expected Growth Rate

Not disclosed in available documents

Growth Strategy

Growth is driven by a dual-segment strategy: 1) Consolidating healthcare through the Plus Care Internationals merger to scale mass screening and diagnostics. 2) Expanding the IT arm into high-demand sectors like e-commerce, banking, and biotechnology through digital transformation and cybersecurity services.

Products & Services

Mass screening, clinical diagnostics, laboratory support, software development, digital transformation consulting, cloud platforms, and cybersecurity solutions.

Brand Portfolio

One Global Service Provider, Plus Care Internationals.

New Products/Services

Expansion into AI-driven digital health and enterprise software solutions for the public sector diagnostics market.

Market Expansion

Targeting underserved regions for healthcare and global markets for IT-enabled services including cloud and data analytics.

Strategic Alliances

Amalgamation with Plus Care Internationals Private Limited, approved by NCLT on March 25, 2025.

🌍 External Factors

Industry Trends

The industry is shifting toward digital health (AI, cloud, data analytics). There is a rising global demand for scalable public health infrastructure and preventive care, which One Global is positioning for through its tech-driven diagnostics.

Competitive Landscape

Faces competition from both local players and multinational corporations in the healthcare and IT consulting sectors.

Competitive Moat

The company's moat is built on its 'dual-focus' model (Healthcare + IT) and its ability to attract specialist physicians. However, this is challenged by intense competition from multinational players and regulatory price caps.

Macro Economic Sensitivity

Highly sensitive to 'inflationary pressures' and 'slowdown in policy making' which affects the rollout of public health programs.

Consumer Behavior

Increased consumer and government focus on 'preventive care' and 'mass screening' is driving demand for the company's diagnostic services.

⚖️ Regulatory & Governance

Industry Regulations

Subject to price controls and capping of margins on medicines by the government. Compliance with State and Central Healthcare coverage schemes impacts overall industry margins.

Legal Contingencies

The Hon’ble National Company Law Tribunal (NCLT), Mumbai Bench, passed an order on March 25, 2025, approving the Scheme of Amalgamation with Plus Care Internationals Private Limited.

⚠️ Risk Analysis

Key Uncertainties

Regulatory changes in healthcare pricing (High impact), failure to fill key managerial vacancies like the CFO (Governance risk), and the risk of 'execution' on large institutional contracts.

Geographic Concentration Risk

Not disclosed, but operations are centered in India with a focus on Mumbai and Ahmedabad for corporate/secretarial functions.

Third Party Dependencies

Dependency on the National Company Law Tribunal for merger approvals and on institutional clients for healthcare revenue.

Technology Obsolescence Risk

The IT segment faces risks from rapid shifts in cloud and AI technologies, requiring continuous investment in innovation.

Credit & Counterparty Risk

Trade Receivables Turnover of 3.67 suggests a collection cycle of approximately 99 days, indicating moderate credit exposure to institutional clients.